je.st
news
Two New Trials of Mercks KEYTRUDA (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016
2016-09-28 12:45:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Results from KEYNOTE-024, which Studied KEYTRUDA Compared to Chemotherapy in Patients with High Levels of PD-L1 Expression, and KEYNOTE-021G, which Studied KEYTRUDA in Combination with Chemotherapy Compared to Chemotherapy Alone in Patients Regardless of PD-L1 Expression, to be Presented Comprehensive Data from Mercks Industry-Leading Immuno-Oncology Clinical Development Program to be Presented, with New Data in 12 Cancers KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that extensive data on KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, have been accepted for presentation at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, Oct. 7 11. In total, findings from 30 studies in 12 cancers from Mercks industry-leading clinical development program for KEYTRUDA both as monotherapy and in combination will be presented at this years ESMO. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: to
advanced
presented
cell
Category:Biotechnology and Pharmaceuticals